|
|
||||||||
|
FJ
EXPRESS SUMMARY ARTICLE The Full-length version of this article is also available, published online March 20, 2001 as doi:10.1096/fj.00-0676fje. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






* Departamento de Bioquímica Médica and
Departamento de Anatomia, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21944590, Brazil; and
Departamento de Ultraestrutura e Biologia Celular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil
2Correspondence: Depto. de Bioquímica Médica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21944590, Brazil. E-mail: ferreira{at}bioqmed.ufrj.br
SPECIFIC AIMS
We have examined the hypothesis that small molecular weight compounds capable of inhibiting the aggregation of the beta-amyloid peptide (Aß) could protect neurons from the toxic effect of Aß and prevent cerebral amyloid deposition. The anti-aggregating and neuroprotective effects of nitrophenols were investigated in vitro using primary cultures of rat hippocampal neurons, and the capacity to inhibit amyloid formation was evaluated in vivo in rats using a model system of cerebral amyloid deposition.
PRINCIPAL FINDINGS
1. Aß fibrils are stabilized by hydrophobic interactions mediated
by the carboxyl-terminal domain of the peptide
Amyloid fibrils were formed in vitro by dissolving either
full-length Aß (Aß1-42 and Aß1-43) or the
carboxyl-terminally truncated Aß128 peptide
in aqueous buffer, and their stabilities in denaturant solutions were
investigated. We found that the stability of fibrillar Aß in
guanidine hydrochloride (GdnHCl) solutions was markedly dependent on
peptide chain length. For Aß128, complete
disaggregation (as indicated by light scattering measurements) was
observed at 3 M GdnHCl, whereas full disaggregation of
Aß142 required 56 M GdnHCl.
All polar and charged amino acid residues of Aß are located in the 28 amino acid-long amino-terminal portion of the peptide. Residues 2942 comprise a cluster of nonpolar amino acids contained in a transmembrane sequence of the amyloid precursor protein. Thus, the higher stabilities of Aß142 and Aß143 relative to Aß128 suggest that the carboxyl-terminal nonpolar amino acid sequence in the former two peptides mediates hydrophobic interactions that are important for the stability of the fibrils. Hydrophobic interactions are known to be destabilized by low temperatures, due to the decrease in the entropic contribution to the hydrophobic effect. In line with this, we found that decreasing temperature from 25°C to 1°C caused reversible and nearly complete disaggregation of Aß. These results indicate that a significant contribution to the stability of Aß aggregates comes from entropy-driven hydrophobic interactions, leading to the hypothesis that hydrophobic compoundssuch as nitrophenolscould be effective in destabilizing and disaggregating amyloid fibrils.
2. Nitrophenols inhibit the aggregation and disaggregate fibrillar
Aß
Addition of micromolar concentrations of 2,4-dinitrophenol (DNP)
or 3-nitrophenol (NP) caused marked disaggregation of previously formed
Aß fibrils, as revealed by light scattering measurements.
IC50 values of approximately 7 µM and 80 µM
were found for DNP and NP, respectively. DNP (20 µM) caused complete
disaggregation of amyloid fibrils. Furthermore, direct demonstration
that DNP and NP inhibited the aggregation of fibrillar amyloid was
obtained by transmission electron microscopy. Abundant fibrils were
observed in control samples of Aß142, whereas
samples in which Aß was added to the medium in the presence of NP or
DNP were completely devoid of fibrils and contained only occasional
scattered amorphous aggregates.
3. Nitrophenols block the neurotoxicity of Aß
To investigate the possible neuroprotective effects of
nitrophenols against Aß-induced neurotoxicity, 48 h primary
cultures of E18 rat hippocampal neurons were used.
Aß142 (44 µM) was added to the medium and
incubation was continued for 72 h. Whereas control hippocampal
neurons exhibited large cell bodies and long, branched neurites
(Fig. 1a
), significant neuronal degeneration and death was observed
after 72 h of culture in the presence of
Aß142 (Fig. 1b
). Large numbers of
Aß-treated neurons became detached from the plate during the
immunostaining washes (Fig. 1b
), suggesting that neuronal
adhesion was impaired. Furthermore, the remaining cell bodies of
Aß-treated neurons were attached to the plate but their neurites were
retracted and thin, and sometimes detached from the plate. When
incubation with Aß was carried out in the presence of NP or DNP, a
marked protection against neurotoxicity was observed (Fig. 1c
, d
, respectively). In the presence of nitrophenols, neurons treated
with Aß showed large cell bodies and long neurites with good adhesion
properties, and the morphological aspect of the cultures was similar to
a control 5 day hippocampal culture.
|
The results obtained in cell culture experiments were quantitated by measuring neuronal survival by trypan blue exclusion. Incubation with Aß142 caused marked cell death, with only 25% neuronal survival vs. 86% survival in control cultures. Remarkably, addition of nitrophenols to the incubation medium almost completely blocked Aß-induced cell death (74% and 65% neuronal survival in the presence of Aß plus DNP or NP, respectively).
4. In vivo inhibition of amyloid deposition
To evaluate the effects of nitrophenols as inhibitors of amyloid
deposition in vivo, we have used a rat model of intracerebral Aß
deposition. Aß was injected alone or in the presence of DNP into the
left or right hippocampi of rats, respectively, and the areas occupied
by amyloid deposits on either side were measured on consecutive
sections stained with thioflavin S. The experimental protocol used was
designed to minimize the influence of individual variability in animal
response by injecting Aß into one hemisphere and an identical amount
of Aß plus DNP into the other hemisphere for each individual rat.
Figure 2a
shows a schematic diagram of the microinjection
protocol, along with representative hippocampal sections stained with
thioflavin S or directly visualized using the autofluorescence of
amyloid, as indicated. The total volume occupied by amyloid deposits
was integrated by image analysis over all consecutive sections spanning
the site of deposition. Figure 2b
, c
, d
, e
shows results of the
integration for four different rats. Coinjection of Aß and DNP
strongly prevented amyloid deposition, with a reduction of 86 ± 17%
in the volume of amyloid deposits in rat brains relative to the volume
occupied when Aß was injected alone (P=0.05,
n=4; one-tailed paired t test).
|
CONCLUSIONS
Despite considerable efforts aiming at understanding the molecular basis and physiopathology of Alzheimers disease, there are currently no clinically accepted treatments to cure or stop the progression of this devastating disease. The ß-amyloid peptide plays a central role in the neuropathology of AD, and considerable evidence indicates that fibrillar aggregation of Aß and amyloid deposition are related to neurotoxicity.
Our study shows that micromolar concentrations of nitrophenols inhibit
the aggregation of Aß in vitro and cause disaggregation of previously
formed amyloid fibrils (Fig. 3
). Of greater interest, nitrophenols protect rat hippocampal neurons in
culture from the neurotoxic effect of Aß (Fig. 3)
. Furthermore,
nitrophenols inhibit the formation of amyloid deposits in rat
hippocampi in an in vivo model system of cerebral amyloid deposition.
|
Nitrophenols are small water-soluble compounds, yet presumably hydrophobic enough to cross the bloodbrain barrier and gain access to the central nervous system. DNP and other nitrophenols are known to be toxic at high concentrations. It is important to note, however, that the nitrophenols by themselves had no detectable toxic effects to neuronal primary cultures at the concentrations used in our studies and that the cytoarchitecture of rat brains (as revealed by staining with cresyl violet) also appeared normal in hemispheres injected with DNP. Finally, because there is no effective treatment currently available for amyloidoses, including Alzheimers disease, type II diabetes, and prion-related spongiform encephalopathies, a possible clinical utilization of nitrophenols at low, subtoxic concentrations should be considered. Another possibility lies in the use of nitrophenols as lead compounds for the development of small molecule inhibitors of amyloidogenesis active at lower concentrations or with fewer undesirable side effects.
In conclusion, we propose that nitrophenols (and/or their derivatives) should be explored as potential therapeutic agents (or lead compounds for further drug development) to prevent the aggregation and neurotoxicity of Aß in Alzheimers disease.
FOOTNOTES
1 To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.00-0676fje ; to cite this article, use FASEB J. (March 20, 2001) 10.1096/fj.00-0676fje ![]()
This article has been cited by other articles:
![]() |
M. Necula, R. Kayed, S. Milton, and C. G. Glabe Small Molecule Inhibitors of Aggregation Indicate That Amyloid beta Oligomerization and Fibrillization Pathways Are Independent and Distinct J. Biol. Chem., April 6, 2007; 282(14): 10311 - 10324. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu, J. Ren, and X. Qu Time-Dependent DNA Condensation Induced by Amyloid {beta}-Peptide Biophys. J., January 1, 2007; 92(1): 185 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cardoso and M. J. Saraiva Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model FASEB J, February 1, 2006; 20(2): 234 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Ferrao-Gonzales, B. K. Robbs, V. H. Moreau, A. Ferreira, L. Juliano, A. P. Valente, F. C. L. Almeida, J. L. Silva, and D. Foguel Controlling {beta}-Amyloid Oligomerization by the Use of Naphthalene Sulfonates: TRAPPING LOW MOLECULAR WEIGHT OLIGOMERIC SPECIES J. Biol. Chem., October 14, 2005; 280(41): 34747 - 34754. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Wasilewska-Sampaio, M. S. Silveira, O. Holub, R. Goecking, F. C. A. Gomes, V. M. Neto, R. Linden, S. T. Ferreira, and F. G. De Felice Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound FASEB J, October 1, 2005; 19(12): 1627 - 1636. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. DE FELICE, M. N. N. VIEIRA, L. M. SARAIVA, J. D. FIGUEROA-VILLAR, J. GARCIA-ABREU, R. LIU, L. CHANG, W. L. KLEIN, and S. T. FERREIRA Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A{beta} oligomerization FASEB J, September 1, 2004; 18(12): 1366 - 1372. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. CARDOSO, G. MERLINI, and M. J. SARAIVA 4'-iodo-4'-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters FASEB J, May 1, 2003; 17(8): 803 - 809. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |